Dafsah Arifa Juzar

Dafsah Arifa Juzar

Auto-generated profile, based on publicly available information

Dafsah Arifa Juzar

Department of Cardiology and Vascular Medicine, Faculty of Medicine, National Cardiovascular Centre Harapan Kita Hospital Jakarta, Universitas Indonesia, Depok, Indonesia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DRDenio A. Ridjab
Denio A. Ridjab
IIIgnatius Ivan
Ignatius Ivan
FBFanny Budiman
Fanny Budiman
DJDafsah A. Juzar
Dafsah A. Juzar
Timing of endotracheal intubation in COVID-19 patients with acute respiratory distress syndrome (ARDS) remains controversial regarding its risk and benefit in patient outcomes. Our study aims to elucidate early versus late intubation outcomes among COVID-19 patients with ARDS. A protocol of this study is registered at the international prospective register of systematic reviews (PROSPERO) (CRD42021230272). We report our systematic review based on PRISMA and MOOSE guidelines. We searched the Cochrane Library, EBSCOhost, EMBASE, Grey Literature Report, OpenGrey, ProQuest, PubMed, and ScienceDirect from inception until 4 December 2021. Titles and abstracts were reviewed for their relevance. The risk of bias in each study was evaluated using the risk of bias in non-randomised studies-of interventions (ROBINS-I) guideline. Trial sequential analysis is done to elucidate firm evidence. We retrieved 20 observational studies that assessed an intervention (early vs. late intubation). Meta-analysis for in-hospital mortality reduction showed 119 fewer deaths per 1000 patients in early intubation. Early intubation reduces 2.81 days of ICU length of stay (LOS) and 2.12 days of ventilation duration. Benefits for mortality and ICU LOS reduction were based on studies with low to moderate risk of bias while ventilation duration was based on low disease burden setting. According to the contextualized approach, the benefit of mortality reduction showed a trivial effect, while ICU LOS and ventilation duration showed a small effect. GRADE certainty of evidence for mortality reduction in early intubation is moderate. The certainty of evidence for ICU length of stay, ventilation duration, ventilator-free days, and continuous renal replacement therapy are very low. This updated systematic review provided new evidence that early intubation might provide benefits in treating COVID-19 patients with ARDS. The benefits of early intubation appear to have an important but small effect based on contextualized approach for ICU LOS and ventilation duration. In reducing in-hospital mortality, the early intubation effect was present but only trivial based on contextualized approach. TSA showed that more studies are needed to elucidate firmer evidence.

13 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Leonardo De LucaLeonardo De Luca
Leonardo De Luca
Magdy AlgowharyMagdy Algowhary
Magdy Algowhary
BUBerat Uguz
Berat Uguz
DODinaldo Oliveira
Dinaldo Oliveira
ВГВладимир Ганюков
Владимир Ганюков
MVMonica Verdoia
Monica Verdoia
The so-called “smoking paradox”, conditioning lower mortality in smokers among STEMI patients, has seldom been addressed in the settings of modern primary PCI protocols. The ISACS–STEMI COVID-19 is a large-scale retrospective multicenter registry addressing in-hospital mortality, reperfusion, and 30-day mortality among primary PCI patients in the era of the COVID-19 pandemic. Among the 16,083 STEMI patients, 6819 (42.3%) patients were active smokers, 2099 (13.1%) previous smokers, and 7165 (44.6%) non-smokers. Despite the impaired preprocedural recanalization (p < 0.001), active smokers had a significantly better postprocedural TIMI flow compared with non-smokers (p < 0.001); this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. Active smokers had a significantly lower in-hospital (p < 0.001) and 30-day (p < 0.001) mortality compared with non-smokers and previous smokers; this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. In conclusion, in our population, active smoking was significantly associated with improved epicardial recanalization and lower in-hospital and 30-day mortality compared with previous and non-smoking history.

Verified
Journal Article
Open access
PDF file
Leonardo De LucaLeonardo De Luca
Leonardo De Luca
Magdy AlgowharyMagdy Algowhary
Magdy Algowhary
BUBerat Uguz
Berat Uguz
DODinaldo Oliveira
Dinaldo Oliveira
ВГВладимир Ганюков
Владимир Ганюков
MVMonica Verdoia
Monica Verdoia
Background: The constraints in the management of patients with ST-segment elevation myocardial infarction (STEMI) during the COVID-19 pandemic have been suggested to have severely impacted mortality levels. The aim of the current analysis is to evaluate the age-related effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI within the registry ISACS-STEMI COVID-19. Methods: This retrospective multicenter registry was performed in high-volume PPCI centers on four continents and included STEMI patients undergoing PPCI in March–June 2019 and 2020. Patients were divided according to age (< or ≥75 years). The main outcomes were the incidence and timing of PPCI, (ischemia time longer than 12 h and door-to-balloon longer than 30 min), and in-hospital or 30-day mortality. Results: We included 16,683 patients undergoing PPCI in 109 centers. In 2020, during the pandemic, there was a significant reduction in PPCI as compared to 2019 (IRR 0.843 (95%-CI: 0.825–0.861, p < 0.0001). We found a significant age-related reduction (7%, p = 0.015), with a larger effect on elderly than on younger patients. Furthermore, we observed significantly higher 30-day mortality during the pandemic period, especially among the elderly (13.6% vs. 17.9%, adjusted HR (95% CI) = 1.55 [1.24–1.93], p < 0.001) as compared to younger patients (4.8% vs. 5.7%; adjusted HR (95% CI) = 1.25 [1.05–1.49], p = 0.013), as a potential consequence of the significantly longer ischemia time observed during the pandemic. Conclusions: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures, with a larger reduction and a longer delay to treatment among elderly patients, which may have contributed to increase in-hospital and 30-day mortality during the pandemic.

23 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Leonardo De LucaLeonardo De Luca
Leonardo De Luca
SSStephane Manzo- Silberman
Stephane Manzo- Silberman
Magdy AlgowharyMagdy Algowhary
Magdy Algowhary
BUBerat Uguz
Berat Uguz
DODinaldo Oliveira
Dinaldo Oliveira
MVMonica Verdoia
Monica Verdoia
Background. Several reports have demonstrated the impact of the COVID-19 pandemic on the management and outcome of patients with ST-segment elevation myocardial infarction (STEMI). The aim of the current analysis is to investigate the potential gender difference in the effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI patients within the ISACS-STEMI COVID-19 Registry. Methods. This retrospective multicenter registry was performed in high-volume primary percutaneous coronary intervention (PPCI) centers on four continents and included STEMI patients undergoing PPCIs in March–June 2019 and 2020. Patients were divided according to gender. The main outcomes were the incidence and timing of the PPCI, (ischemia time ≥ 12 h and door-to-balloon ≥ 30 min) and in-hospital or 30-day mortality. Results. We included 16683 STEMI patients undergoing PPCIs in 109 centers. In 2020 during the pandemic, there was a significant reduction in PPCIs compared to 2019 (IRR 0.843 (95% CI: 0.825–0.861, p < 0.0001). We did not find a significant gender difference in the effects of the COVID-19 pandemic on the numbers of STEMI patients, which were similarly reduced from 2019 to 2020 in both groups, or in the mortality rates. Compared to prepandemia, 30-day mortality was significantly higher during the pandemic period among female (12.1% vs. 8.7%; adjusted HR [95% CI] = 1.66 [1.31–2.11], p < 0.001) but not male patients (5.8% vs. 6.7%; adjusted HR [95% CI] = 1.14 [0.96–1.34], p = 0.12). Conclusions. The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures similarly observed in both genders. Furthermore, we observed significantly increased in-hospital and 30-day mortality rates during the pandemic only among females. Trial registration number: NCT 04412655.

25 November 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ASAnindya Pradipta Susanto
Anindya Pradipta Susanto
DLDavid Lyell
David Lyell
BWBambang Widyantoro
Bambang Widyantoro
DJDafsah Arifa Juzar
Dafsah Arifa Juzar
ASAnwar Santoso
Anwar Santoso
FMFarah Magrabi
Farah Magrabi
Background: Preventive strategies integrated with digital health and artificial intelligence (AI) have significant potential to mitigate the global burden of atherosclerotic cardiovascular disease (ASCVD). AI-enabled clinical decision support (CDS) systems increasingly provide patient-specific insights beyond traditional risk factors. Despite these advances, their capacity to enhance clinical decision-making in resource-constrained settings remains largely unexplored. Objective: We conducted a randomized controlled study to assess the effect of AI-based CDS on 10-year ASCVD risk assessment and management in primary prevention. Methods: In a 3-way, within-subject randomized design, doctors completed 9 clinical vignettes representative of primary care presentations in a resource-constrained outpatient setting. For each vignette, participants assessed 10-year ASCVD risk and made management decisions using a conceptual prototype of AI-based CDS, automated CDS, or no decision support. The conceptual prototype represented contemporary risk calculators based on traditional machine learning models (eg, random forest, neural networks, logistic regression) that incorporate additional predictors alongside traditional risk factors. Primary outcomes were correct risk assessment and patient management (prescription of aspirin, statins, and antihypertensives; referral for advanced examinations). Decision-making time and perceptions about AI utility were also measured. Results: In total, 102 doctors from all 7 geographical regions of Indonesia participated. Most (n=85, 83%) participants were 26‐35 years of age, and 57 (56%) were male, with a median of 6 (IQR 4.75) years of clinical experience. AI-based CDS improved risk assessment by 27% ( χ 2 2 (n=102)=48.875, P <.001) when compared to unassisted risk assessment, equating to 1 additional correct risk classification for every 3.7 patients where doctors used AI (number needed to treat=3.7, 95% CI 2.9-5.2). The prescription of statins also improved by 29% ( χ 2 2 (n=102)=36.608, P <.001). In pairwise comparisons, doctors who were assisted by the AI-based CDS correctly assessed significantly more cases (z=−5.602, n=102, adjusted P <.001) and prescribed the appropriate statin more often ( z =−4.936, adjusted P <.001, medium effect size r =0.35) when compared with the control. AI-assisted cases required less time (estimated marginal means 63.6 s vs 72.8 s, F 2, 772.8 =5.710, P =.003). However, improvements in the prescription of aspirin and antihypertensives did not reach statistical significance ( P =.08 and P =.30, respectively). No improvement was observed in referral decisions. Participants generally viewed AI-based CDS positively, with 81 (79%) agreeing or strongly agreeing that they would follow its recommendations and 82 (82%) indicating they would use it if given access. They believed CDS could enhance the efficiency of risk assessment, particularly in high-volume primary care settings, while noting the need to verify AI recommendations against clinical guidelines for each patient. Conclusions: Improvements in risk assessment and statin prescription, coupled with reduced decision-making time, highlight the potential utility of AI in ASCVD risk assessment, particularly in resource-constrained settings where efficient use of health care resources and doctors’ time is crucial. Further research is needed to ascertain whether improvements observed in this online study translate to real-world low-resource settings.

27 August 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
REReza Ishak Estiko
Reza Ishak Estiko
BWBambang Widyantoro
Bambang Widyantoro
DJDafsah Arifa Juzar
Dafsah Arifa Juzar
RYRamdhan Maulana Yusup
Ramdhan Maulana Yusup
IRIqbal Fauzi Rakhmat
Iqbal Fauzi Rakhmat
EREstiko Rijanto
Estiko Rijanto
Objective This study aimed to screen for hypertension in a vast Indonesian population using machine learning (ML) and 11 non-laboratory risk factors, validating the results through internal and external validations. Setting and participants From the initial 1 782 365 participants aged 15 and above registered at the Integrated Counseling Post primary care centres across Indonesia from 2014 to 2017, incomplete data and outliers were excluded, and 268 210 participants were included in our analysis. The dataset was split deterministically into a dataset for training using 10-fold internal cross-validation of 204 315 participants and another dataset for external validation of 63 895 participants. Design This retrospective cross-sectional study used three ML algorithms, that is, random forest, gradient boosting and extreme gradient boosting (XGBoost), and compared them against logistic regression as a benchmark to screen hypertension based on the WHO and International Society of Hypertension criteria. The importance of the risk factors was ranked. By partly using continuous versus categorical age, waist circumference (WC) and body mass index (BMI) risk factors, we evaluated the screening performance regarding sensitivity and area under the receiver operating characteristic curve (AUC). Results The external validations revealed that the XGBoost model performed the best in hypertension screening. The external validation, which partly uses continuous variables, provides 0.97 sensitivity and 0.75 AUC, indicating excellent screening capability. The importance rank of the risk factors was consecutively family history of hypertension (FH-HTN), age, WC, BMI, occupation, education, sex, smoking, low physical activity, lack of fruit or vegetable intake and alcohol consumption. Conclusions By using 11 easy-to-collect non-laboratory risk factors, the ML model successfully screens for hypertension with better performance than the benchmark. Using the numerical variables of age, WC and BMI yields a better discrimination capability than the categorical variables. FH-HTN and age are the two top risk factors for the development of hypertension. This study is a useful academic exercise and shows ML’s importance in handling large data sets.